Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Enrollment
- 11
- Primary Endpoint
- VLDL-apoC-III transport rate
Study Overview
Brief Summary
The purpose of this study is to determine whether atorvastatin and fenofibrate are effective in the treatment of lipid disorders in obese, insulin resistant subjects.
Detailed Description
Insulin resistance is a heterogeneous metabolic disorder of complex etiology. It underpins dyslipoproteinemia, a key feature of the metabolic syndrome (MetS) that independently predicts cardiovascular disease (CVD). Hypertriglyceridemia, the most consistent lipid disorder in subjects with obesity and type 2 diabetes mellitus, is chiefly a consequence of overproduction and delayed clearance of triglyceride-rich lipoproteins (TRLs). Although the precise mechanisms involved are incompletely understood, experimental and clinical evidence suggests that elevated apolipoprotein (apo) C-III may play a crucial role in the dysregulation of TRL metabolism. investigating the effects of these agents on VLDL-apoC-III kinetics. In this study, we aimed to examine the effect of two lipid-regulating agents, atorvastatin and fenofibrate on VLDL-apoC-III transport. We hypothesized that atorvastatin and fenofibrate would have similar effects on apoC-III transport by decreasing the production and increasing the catabolism of VLDL-apoC-III.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 25 Years to 70 Years (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •any three of the followings
- •waist circumference >102cm
- •triglycerides >1.7 mmol/L
- •HDL-cholesterol <1.05 mmol/L
- •blood glucose >6.1 mmol/L
- •blood pressure >130/85mmHg
Exclusion Criteria
- •plasma cholesterol >7mmo/L
- •triglycerides >4.5mmo/L
- •diabetes mellitus (defined by oral glucose tolerance test)
- •consumption of >30g alcohol/day
- •use of agents affecting lipid metabolism
- •APOE2/E2 genotype, macroproteinuria
- •creatinaemia (>120umol/L)
- •hypothyroidism
- •abnormal liver and muscle enzymes.
Arms & Interventions
P
placebo group
Intervention: Atorvastatin and fenofibrate (Drug)
Feno
Fenofibrate
Intervention: Atorvastatin and fenofibrate (Drug)
ATV
Atorvastatin
Intervention: Atorvastatin and fenofibrate (Drug)
Outcomes
Primary Outcomes
VLDL-apoC-III transport rate
Time Frame: 5 weeks
Secondary Outcomes
No secondary outcomes reported